Find Lusutrombopag manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1110766-97-6, Mulpleta, S-888711, 6ll5jfu42f, Rsc888711, (e)-3-[2,6-dichloro-4-[[4-[3-[(1s)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
Molecular Formula
C29H32Cl2N2O5S
Molecular Weight
591.5  g/mol
InChI Key
NOZIJMHMKORZBA-KJCUYJGMSA-N
FDA UNII
6LL5JFU42F

Lusutrombopag
Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well, including erythroid, granulocytic and lymphoid lineages. Thrombocytopenia, which indicates abnormally low levels of platelets, is a common complication related to chronic liver disease. This hematological abnormality, especially in cases of severe thrombocytopenia (platelet count <50,000/L), creates challenges to patients requiring invasive medical procedures where there is a significant risk for spontaneous bleeding. Lusutrombopag binds to the transmembrane domain of TPOR expressed on megakaryocytes, and causes the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells. In September 2015, lusutrombopag received its first global approval in Japan to reduce the need for platelet transfusion in adults with chronic liver disease and thrombocytopenia who are schedule to undergo an invasive medical procedure. Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. In two randomized, double-blind, placebo-controlled trials, patients with chronic liver disease and severe thrombocytopenia who were undergoing an invasive procedure with a platelet count less than 50 x 10^9/L were administered lusutrombopag orally. Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo. Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK.
1 2D Structure

Lusutrombopag

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-3-[2,6-dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
2.1.2 InChI
InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1
2.1.3 InChI Key
NOZIJMHMKORZBA-KJCUYJGMSA-N
2.1.4 Canonical SMILES
CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl
2.1.5 Isomeric SMILES
CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl
2.2 Other Identifiers
2.2.1 UNII
6LL5JFU42F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Mulpleta

2.3.2 Depositor-Supplied Synonyms

1. 1110766-97-6

2. Mulpleta

3. S-888711

4. 6ll5jfu42f

5. Rsc888711

6. (e)-3-[2,6-dichloro-4-[[4-[3-[(1s)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic Acid

7. (s,e)-3-(2,6-dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic Acid

8. (2e)-3-(2,6-dichloro-4-((4-(3-((1s)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic Acid

9. Lusutrombopag [inn]

10. Unii-6ll5jfu42f

11. Lusutrombopag [usan:inn]

12. Mulpleta (tn)

13. 2-propenoic Acid, 3-(2,6-dichloro-4-(((4-(3-((1s)-1-(hexyloxy)ethyl)-2-methoxyphenyl)-2-thiazolyl)amino)carbonyl)phenyl)-2-methyl-, (2e)-

14. S 888711

15. Lusutrombopags-888711

16. Lusutrombopag [mi]

17. Lusutrombopag [jan]

18. Lusutrombopag [usan]

19. Lusutrombopag [who-dd]

20. Schembl3062080

21. Schembl3062084

22. Chembl2107831

23. Lusutrombopag (jan/usan/inn)

24. Gtpl10032

25. Chebi:136051

26. Dtxsid701027951

27. Lusutrombopag [orange Book]

28. 2-propenoic Acid, 3-[2,6-dichloro-4-[[[4-[3-[(1s)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2e)-

29. Ex-a1290

30. Mfcd28502075

31. S6988

32. Zinc84759273

33. Cs-6137

34. Db13125

35. Ncgc00522464-01

36. (2e)-3-(2,6-dichloro-4-((4-(3-((1s)-1-(hexyloxy)ethyl)- 2-methoxyphenyl)-1,3-thiazol-2-yl)carbamoyl)phenyl)-2-methylprop-2-enoic Acid

37. Ac-30601

38. As-52368

39. Hy-19883

40. J3.505.027b

41. D10476

42. A927042

43. S888711

44. Q27265116

45. (e)-3-[2,6-dichloro-4-[4-[3-[(s)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic Acid

2.4 Create Date
2011-01-31
3 Chemical and Physical Properties
Molecular Weight 591.5 g/mol
Molecular Formula C29H32Cl2N2O5S
XLogP37.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count13
Exact Mass590.1408987 g/mol
Monoisotopic Mass590.1408987 g/mol
Topological Polar Surface Area126 Ų
Heavy Atom Count39
Formal Charge0
Complexity822
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.


FDA Label


Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures


Treatment of thrombocytopenia secondary to liver disease


5 Pharmacology and Biochemistry
5.1 Pharmacology

The AUC of lusutrombopag was found to correlate the increased platelet counts. Following administration of 3 mg daily dose in patients with chronic liver disease and thrombocytopenia, the mean (standard deviation) maximum platelet count in patients (N=74) without platelet transfusion was 86.9 (27.2) 10^9/L, and the median time to reach the maximum platelet count was 12.0 (5 to 35) days. Lusutrombopag was not shown to induce any clinically significant QTc prolongation at a dose 8 times the recommended dosage.


5.2 ATC Code

B02BX


B - Blood and blood forming organs

B02 - Antihemorrhagics

B02B - Vitamin k and other hemostatics

B02BX - Other systemic hemostatics

B02BX07 - Lusutrombopag


5.3 Absorption, Distribution and Excretion

Absorption

Lusutrombopag is rapidly absorbed following oral administration. It exhibited a doseproportional pharmacokinetic profile over the single dose range of 1 mg to 50 mg, which was similar in both healthy subjects and those with chronic liver disease. A geometric mean (%CV) maximal concentration (Cmax) and area under the curve (AUC) in healthy subjects receiving 3 mg of lusutrombopag were 111 (20.4) ng/mL and 2931 (23.4) ng.hr/mL. The accumulation ratios of Cmax and AUC were approximately 2 with oncedaily multipledose administration, and steadystate plasma lusutrombopag concentrations were achieved after Day 5. The time to reach peak plasma concentrations (Tmax) were approximately 6 to 8 hours after oral administration in patients with chronic liver disease. Food consumption is not reported to affect the absorption and bioavailability of lusutrombopag.


Route of Elimination

About 1% of the administered dose of lusutrombopag undergoes urinary excretion. Fecal excretion accounted for 83% of the total dose, where 16% of the dose was excreted as unchanged parent compound.


Volume of Distribution

The mean (%CV) lusutrombopag apparent volume of distribution in healthy adult subjects was 39.5 (23.5) L.


Clearance

The approximate mean (%CV) clearance of lusutrombopag in patients with chronic liver disease is estimated to be 1.1 (36.1) L/hr.


5.4 Metabolism/Metabolites

CYP4 enzymes predominantly contribute to the metabolism of lusutrombopag, especially CYP4A11. Lusutrombopag is reported to mainly undergo - and -oxidation, as well as glucuronidation.


5.5 Biological Half-Life

In healthy adult subjects, the terminal elimination halflife (t1/2) was approximately 27 hours.


5.6 Mechanism of Action

Lusutrombopag mimics the biological actions of endogenous thrombopoietin (TPO) by acting as an agonist for the thrombopoietin receptor (TPOR) expressed on megakaryocytes. It binds to the transmembrane domain of the receptor and induces thrombocytopoiesis by targeting the same signal transduction system as that of endogenous TPO, which involves the activation of JAK and STAT pathways. It stimulates the proliferation and differentiation of bone marrow progenitor cells into megakaryocytes, which undergoes maturation to act as precursor cells for platelets. A single megakaryocyte produces and releases thousands of platelets upon maturation and series of remodeling events. Lusutrombopag displays high specificity towards human TPORs when compared to murine TPORs. Lusutrombopag may affect other hematopoietic lineages as well, including erythroid, granulocytic and lymphoid lineages. One case of increased leukocyte and erythrocyte counts that prolonged for over 120 days was reported following administration in a patient with liver cirrhosis (LC) due to hepatitis C virus.


API SUPPLIERS

read-more
read-more

01

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

LUSUTROMBOPAG

NDC Package Code : 53044-003

Start Marketing Date : 2018-08-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Lusutrombopag

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

VANCOCIN ITALIA

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

VANCOCIN ITALIA

Country
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

LUSUTROMBOPAG

US Patent Number : 8530668

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210923

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-21

blank

02

VANCOCIN ITALIA

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

VANCOCIN ITALIA

Country
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

LUSUTROMBOPAG

US Patent Number : 7601746

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210923

Patent Use Code : U-2344

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2024-09-05

blank

03

VANCOCIN ITALIA

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

VANCOCIN ITALIA

Country
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

LUSUTROMBOPAG

US Patent Number : 9427402

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210923

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2031-09-29

blank

04

VANCOCIN ITALIA

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

VANCOCIN ITALIA

Country
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

LUSUTROMBOPAG

US Patent Number : 8889722

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210923

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-07-29

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Lusutrombopag Manufacturers

A Lusutrombopag manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lusutrombopag, including repackagers and relabelers. The FDA regulates Lusutrombopag manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lusutrombopag API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Lusutrombopag manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Lusutrombopag Suppliers

A Lusutrombopag supplier is an individual or a company that provides Lusutrombopag active pharmaceutical ingredient (API) or Lusutrombopag finished formulations upon request. The Lusutrombopag suppliers may include Lusutrombopag API manufacturers, exporters, distributors and traders.

click here to find a list of Lusutrombopag suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Lusutrombopag NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lusutrombopag as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Lusutrombopag API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Lusutrombopag as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Lusutrombopag and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lusutrombopag NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Lusutrombopag suppliers with NDC on PharmaCompass.

Lusutrombopag GMP

Lusutrombopag Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lusutrombopag GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lusutrombopag GMP manufacturer or Lusutrombopag GMP API supplier for your needs.

Lusutrombopag CoA

A Lusutrombopag CoA (Certificate of Analysis) is a formal document that attests to Lusutrombopag's compliance with Lusutrombopag specifications and serves as a tool for batch-level quality control.

Lusutrombopag CoA mostly includes findings from lab analyses of a specific batch. For each Lusutrombopag CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lusutrombopag may be tested according to a variety of international standards, such as European Pharmacopoeia (Lusutrombopag EP), Lusutrombopag JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lusutrombopag USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty